论文部分内容阅读
目的:分析卡培他滨维持化疗对胃癌晚期的临床效果。方法:抽取2012年4月-2014年6月梁平县人民医院化疗后体征稳定的胃癌晚期患者54例,随机分为观察组和对照组各27例,对照组予以常规治疗,观察组在常规治疗的基础上给予卡培他滨口服维持化疗,比较两组患者的治疗效果。结果:观察组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05),两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡培他滨维持化疗对于胃癌晚期,能有效延长患者生存期,提高患者生存率,近期疗效显著,且毒副作用均表现为耐受。
Objective: To analyze the clinical effect of capecitabine in maintenance chemotherapy on advanced gastric cancer. Methods: From April 2012 to June 2014, 54 patients with stable gastric cancer after chemotherapy in Liangping County People’s Hospital were randomly divided into observation group and control group, with 27 cases in each group. The control group was treated routinely, and the observation group received routine treatment On the basis of capecitabine given to maintain chemotherapy, the treatment effect of two groups were compared. Results: The total effective rate of observation group was significantly higher than that of control group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The maintenance of capecitabine for advanced gastric cancer, can effectively prolong the survival of patients and improve patient survival rate, the recent significant effect, and the side effects are manifested as tolerance.